Chronix Biomedical, Inc. is a molecular diagnostics company offering laboratory developed blood tests to doctors for cancer screening supplemental evaluations and monitoring cancer through its own certified laboratories. Chronix is privately held with headquarters in San Jose, California, and laboratories in Göttingen, Germany. Currently, Chronix Biomedical is offering 4 different tests.
Treatment Monitoring Test
A blood test that indicates whether a treatment is working in one to two cycles of therapy with over 90% positive predictive value.
CNI cancer evaluation test
A blood test that reveals mutations mostly seen in patients with cancer.
Second Opinion™ prostate cancer evaluation test
A blood test for men with elevated PSA that reveals the mutations mostly seen in patients with prostate cancer.
Second Opinion™ breast cancer evaluation test
A blood test for patients with abnormal mammograms or lumps that reveals the mutations mostly seen in patients with breast cancer.
Due to the fact, that Chronix Biomedical is seeking to move part of its Research and Development efforts to Poland, the Company has established a subsidiary there (Crow 24 Sp. z o. o., name is currently in the process of change into Chronix Polska). Chronix Polska is now seeking a Polish clinical subcontractors for its research and development projects. Please click here for more details.
“The knowledge that we have gained over the past year now suggests to us that we are able to provide to doctors and their patients the ability to diagnose at the most earliest stage the presence of cancer in their body.”
Howard Urnovitz, CEO of Chronix Biomedical for The Times
“We believe our cancer blood tests will lead to a world where no one dies unnecessarily of cancer.”
Howard Urnovitz, CEO of Chronix Biomedical